Patents by Inventor Christian Stratowa

Christian Stratowa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of ameliorating the harmful effects of TNF using a polypeptide having the ability to bind to TNF
    Patent number: 7282483
    Abstract: The present invention provides DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. Recombinant TNF-binding protein is used in pharmaceutical preparations for treating indications in which TNF has a harmful effect. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.
    Type: Grant
    Filed: July 3, 2001
    Date of Patent: October 16, 2007
    Assignee: Amgen Inc.
    Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
  • TNF receptors, TNF binding proteins and DNAs coding for them
    Patent number: 7264944
    Abstract: The present invention provides DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. Recombinant TNF-binding protein is used in pharmaceutical preparations for treating indications in which TNF has a harmful effect. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.
    Type: Grant
    Filed: March 15, 2000
    Date of Patent: September 4, 2007
    Assignee: Amgen Inc.
    Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
  • TNF binding proteins
    Patent number: 7238776
    Abstract: The present invention provides DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. Recombinant TNF-binding protein is used in pharmaceutical preparations for treating indications in which TNF has a harmful effect. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.
    Type: Grant
    Filed: July 3, 2001
    Date of Patent: July 3, 2007
    Assignee: Amgen Inc.
    Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
  • TNF receptors, TNF binding proteins and DNAs coding for them
    Publication number: 20020183485
    Abstract: DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. Recombinant TNF-binding protein is used in pharmaceutical preparations for treating indications in which TNF has a harmful effect. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.
    Type: Application
    Filed: February 23, 2001
    Publication date: December 5, 2002
    Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
  • TNF receptors, TNF binding proteins and DNAs coding for them
    Publication number: 20020169118
    Abstract: DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. Recombinant TNF-binding protein is used in pharmaceutical preparations for treating indications in which TNF has a harmful effect. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.
    Type: Application
    Filed: July 3, 2001
    Publication date: November 14, 2002
    Applicant: Amgen, Inc.
    Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
  • TNF receptors, TNF binding proteins and DNAs coding for them
    Publication number: 20020155112
    Abstract: DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. Recombinant TNF-binding protein is used in pharmaceutical preparations for treating indications in which TNF has a harmful effect. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.
    Type: Application
    Filed: July 3, 2001
    Publication date: October 24, 2002
    Applicant: Amgen, Inc.
    Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
  • TNF receptors, TNF binding proteins and DNAS coding for them
    Patent number: 6440693
    Abstract: DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. Recombinant TNF-binding protein is used in pharmaceutical preparations for treating indications in which TNF has a harmful effect. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: August 27, 2002
    Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
  • TNF receptors, TNF binding proteins and DNAs coding for them
    Publication number: 20020090676
    Abstract: DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. Recombinant TNF-binding protein is used in pharmaceutical preparations for treating indications in which TNF has a harmful effect. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.
    Type: Application
    Filed: July 3, 2001
    Publication date: July 11, 2002
    Applicant: Amgen, Inc.
    Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
  • Method of ameliorating the harmful effects of TNF using a polypeptide having the ability to bind to TNF
    Patent number: 6417158
    Abstract: DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. Recombinant TNF-binding protein is used in pharmaceutical preparations for treating indications in which TNF has a harmful effect. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: July 9, 2002
    Assignee: Amgen, Inc.
    Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
  • TNF receptors, TNF binding proteins and DNAs coding for them
    Patent number: 6294352
    Abstract: DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequence can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. Recombinant TNF-binding protein is used in pharmaceutical preparations for treating indications in which TNF has a harmful effect. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.
    Type: Grant
    Filed: February 1, 1995
    Date of Patent: September 25, 2001
    Assignee: Amgen Inc.
    Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
  • TNF Receptors, TNF binding proteins and DNAs coding for them
    Patent number: 6271346
    Abstract: DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. Recombinant TNF-binding protein is used in pharmaceutical preparations for treating indications in which TNF has a harmful effect. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: August 7, 2001
    Assignee: Amgen Inc.
    Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
  • TNF receptors, TNF binding proteins and DNAs coding for them
    Patent number: 6221675
    Abstract: DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF is receptor and/or for their effect on the biological activity of TNF.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: April 24, 2001
    Assignee: Amgen, Inc.
    Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
  • Process for screening substances capable of modulating a receptor-dependent cellular signal transmission path
    Patent number: 5854004
    Abstract: A process is disclosed for screening substances having a modulating effect on a receptor-dependent signal transmission path in mammal cells. Test cells are used transformed with a reporter gene and with a regulatory sequence functionally linked thereto sensitive to the IP.sub.3 /DAG concentration, as well as with a coding DNA for a receptor coupled to the phospholipase effector system, in particular a G protein-coupled receptor. The use of reference cells without receptor DNA and reference cells with specificity for the adenylate cyclase effector system allows substances to be identified having potential pharmacological action and specificity for a determined receptor-dependent signal transmission path.
    Type: Grant
    Filed: May 25, 1994
    Date of Patent: December 29, 1998
    Assignee: Boehringer Ingleheim GmbH
    Inventors: Armin Peter Czernilofsky, Adolf Himmler, Christian Stratowa, Ulrike Weyer, Herbert Lamche, Renate Schafer
  • TNF receptors, TNF binding proteins and DNAs coding for them
    Patent number: 5843791
    Abstract: DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein constitutes the soluble domain. The DNA sequences can be used for preparing recombinant DNA molecules in order to produce TNF-binding protein and TNF receptor. With the aid of the TNF receptor or fragments thereof or with the aid of suitable host organisms transformed with recombinant DNA molecules containing the DNA which codes for the TNF receptor or fragments or modifications thereof, it is possible to investigate substances for their interaction with the TNF receptor and/or for their effect on the biological activity of TNF.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 1, 1998
    Assignee: Amgen Boulder Inc.
    Inventors: Rudolf Hauptmann, Adolf Himmler, Ingrid Maurer-Fogy, Christian Stratowa
  • Vascular anticoagulant proteins DNA which codes them, processer for preparing them and their use
    Patent number: 5837842
    Abstract: This invention relates to biologically active proteins, the DNA molecules coding for them, processes for preparing them and their use.
    Type: Grant
    Filed: January 23, 1995
    Date of Patent: November 17, 1998
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Rudolf Hauptmann, Ingrid Maurer-Fogy, Gerhard Bodo, Peter Swetly, Christian Stratowa, Edgar Falkner, Gunther Adolf, Christiaan Maria Peter Reutelingsperger
  • Human manganese superoxide dismutase (hMn-SOD)
    Patent number: 5589371
    Abstract: The present invention relates to a method of preparing human Mn-superoxide dismutase (hMn-SOD) by genetic engineering, the DNA sequences which code for this enzyme, suitable vectors which contain these DNA sequences and host cells which can express these DNA sequences, and the enzyme hMn-SOD itself. Suggestions as to the use of this enzyme are also described.
    Type: Grant
    Filed: March 30, 1995
    Date of Patent: December 31, 1996
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Konrad Heckl, Walter Spevak, Elinborg Ostermann, Andreas Zophel, Edeltraud Krystek, Ingrid Maurer-Fogy, Maria J. Wiche-Castanon, Christian Stratowa, Rudolf Hauptmann
  • Human manganese superoxide dismutase (hMn-SOD)
    Patent number: 5436162
    Abstract: The present invention relates to a method of preparing human Mn-superoxide dismutase (hMn-SOD) by genetic engineering, the DNA sequences which code for this enzyme, suitable vectors which contain these DNA sequences and host cells which can express these DNA sequences, and the enzyme hMn-SOD itself. Suggestions as to the use of this enzyme are also described.
    Type: Grant
    Filed: September 15, 1992
    Date of Patent: July 25, 1995
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Konrad Heckl, Walter Spevak, Elinborg Ostermann, Andreas Zophel, Edeltraud Krystek, Ingrid Maurer-Fogy, Maria J. Wiche-Castanon, Christian Stratowa, Rudolf Hauptmann
  • Human manganese superoxide dismutase (hMn-SOD)
    Patent number: 5260204
    Abstract: The present invention relates to a method of preparing human Mn-superoxide dismutase (hMn-SOD) by genetic engineering, the DNA sequences which code for this enzyme, suitable vectors which contain these DNA sequences and host cells which can express these DNA sequences, and the enzyme hMn-SOD itself. Suggestions as to the use of this enzyme are also described.
    Type: Grant
    Filed: September 15, 1992
    Date of Patent: November 9, 1993
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Konrad Heckl, Walter Spevak, Elinborg Ostermann, Andreas Zophel, Edeltraud Krystek, Ingrid Maurer-Fogy, Maria J. Wiche-Castanon, Christian Stratowa, Rudolf Hauptmann
  • Human manganese superoxide dismutase (hMn-SOD)
    Patent number: 5240847
    Abstract: The present invention relates to a method of preparing human Mn-superoxide dismutase (hMn-SOD) by genetic engineering, the DNA sequences which code for this enzyme, suitable vectors which contain these DNA sequences and host cells which can express these DNA sequences, and the enzyme hMn-SOD itself. Suggestions as to the use of this enzyme are also described.
    Type: Grant
    Filed: March 11, 1988
    Date of Patent: August 31, 1993
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Konrad Heckl, Walter Spevak, Elinborg Ostermann, Andreas Zophel, Edeltraud Krystek, Ingrid Maurer-Fogy, Maria J. Wiche-Castanon, Christian Stratowa, Rudolf Hauptmann